Dopexamine

Structural formula
General
Surname	Dopexamine
other names	4- [2 - ({6 - [(2-Phenylethyl) amino] hexyl} amino) ethyl] -1,2-benzenediol ( IUPAC )
Molecular formula	C 22 H 32 N 2 O 2
External identifiers / databases
PubChem	55483
ChemSpider	50102
Wikidata	Q5297311
Drug information
ATC code	C01 CA14
Drug class	Catecholamines
Mechanism of action	Beta-1 and Beta-2 sympathomimetics
properties
Molar mass	429.43 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dopexamine is a chemical compound from the group of catecholamines , which is used in medicine as a medicinal substance in the treatment of heart failure . The substance acts as a beta-1 and beta-2 sympathomimetic .

Clinical information

It is used in acute therapy for severe heart failure at a dose of 1–4 µg / kg / min. The administration is contraindicated in the presence of angina pectoris and pulmonary embolism .

Pharmacological properties

Dopexamine has a strong adrenergic β and DA ₁ receptor effect and thus leads to vasodilation and a reduction in afterload, which leads to an increase in the oxygen supply and the cardiac output . It also inhibits the reuptake of norepinephrine at neural nerve endings. This inhibition is about ten times stronger with dopexamine than with the pharmacological analogue dopamine . It does not have a vasoconstrictive effect. Dopexamine has been thought to have a positive effect on splanchnic perfusion, but the data on this are contradicting. Dopexamine has a slightly positive inotropic effect .

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ C. Estler, H. Schmidt: Pharmakologie und Toxikologie . 6., completely revised u. exp. Edition. Schattauer 2006. ISBN 978-3794522958 , p. 506.
↑ Reinhard Larsen: Anesthesia and intensive medicine in cardiac, thoracic and vascular surgery. (1st edition 1986) 5th edition. Springer, Berlin / Heidelberg / New York et al. 1999, ISBN 3-540-65024-5 , pp. 44-50.
↑ Mitchell, Smith, et al. a .: Inhibition of uptake 1 by dopexamine hydrochloride in vitro . In: British Journal of Pharmacology . 1987; 92: 265ff.
↑ F. Kreuz, F. Teufel: Anesthesia and intensive medicine . Springer 2006. ISBN 978-3540627395 . P. 50.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] C. Estler, H. Schmidt: Pharmakologie und Toxikologie . 6., completely revised u. exp. Edition. Schattauer 2006. ISBN 978-3794522958 , p. 506.

[3] Reinhard Larsen: Anesthesia and intensive medicine in cardiac, thoracic and vascular surgery. (1st edition 1986) 5th edition. Springer, Berlin / Heidelberg / New York et al. 1999, ISBN 3-540-65024-5 , pp. 44-50.

[4] Mitchell, Smith, et al. a .: Inhibition of uptake 1 by dopexamine hydrochloride in vitro . In: British Journal of Pharmacology . 1987; 92: 265ff.

[5] F. Kreuz, F. Teufel: Anesthesia and intensive medicine . Springer 2006. ISBN 978-3540627395 . P. 50.